Zoetis Inc

ZTS-N

NYSE:ZTS

160.19
0.87 (0.54%)
Zoetis, Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of ...
More at Wikipedia

Analysis and Opinions about ZTS-N

Signal
Opinion
Expert
BUY
BUY
October 26, 2020
A lot more people have either bought or adopted pets. The cost of keeping an animal has gotten more expensive. You should buy on a pull back. It is a great demographic story.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
October 26, 2020
A lot more people have either bought or adopted pets. The cost of keeping an animal has gotten more expensive. You should buy on a pull back. It is a great demographic story.
HOLD
HOLD
October 21, 2020
He took profits to switch into biotech. Revenue streams will grow at high single digits. Chart looks good. One of his favourite names in the space.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
October 21, 2020
He took profits to switch into biotech. Revenue streams will grow at high single digits. Chart looks good. One of his favourite names in the space.
PAST TOP PICK
PAST TOP PICK
August 20, 2020
(A Top Pick Sep 26/19, Up 26%) Pharmaceuticals for pets and livestock. Beat revenue by 11% on pets. Livestock side was down, but rose at 5%. Great company and demographic growth. If you see a pullback, buy.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
August 20, 2020
(A Top Pick Sep 26/19, Up 26%) Pharmaceuticals for pets and livestock. Beat revenue by 11% on pets. Livestock side was down, but rose at 5%. Great company and demographic growth. If you see a pullback, buy.
HOLD
HOLD
August 7, 2020
An animal health company. He has concerns over livestock exposure, especially with people wanting less chemicals and antibiotics in livestock. The pet market side of the business is more positive.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
August 7, 2020
An animal health company. He has concerns over livestock exposure, especially with people wanting less chemicals and antibiotics in livestock. The pet market side of the business is more positive.
TOP PICK
TOP PICK
June 26, 2020
An animal health care company that works with pets and livestock. There is over $15 billion in pet spending in the US today. There is not the same price pressure in pet health from insurance companies like in pharma. Getting a drug for a pet is easier and faster than for human use. On the livestock side, developing countries are consuming more protein. Yield 0.59% (Analysts’ price target is $136.14)
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
June 26, 2020
An animal health care company that works with pets and livestock. There is over $15 billion in pet spending in the US today. There is not the same price pressure in pet health from insurance companies like in pharma. Getting a drug for a pet is easier and faster than for human use. On the livestock side, developing countries are consuming more protein. Yield 0.59% (Analysts’ price target is $136.14)
PAST TOP PICK
PAST TOP PICK
May 11, 2020
(A Top Pick May 21/19, Up 24%) Pets as well as livestock. There is not a lot of generics for pet drugs. A lot are the same as for pets as for humans.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
May 11, 2020
(A Top Pick May 21/19, Up 24%) Pets as well as livestock. There is not a lot of generics for pet drugs. A lot are the same as for pets as for humans.
PAST TOP PICK
PAST TOP PICK
March 12, 2020
(A Top Pick May 21/19, Up 18%) Pharma company for animals, livestock and pets. Great story. Great company and an opportunity to do well.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
March 12, 2020
(A Top Pick May 21/19, Up 18%) Pharma company for animals, livestock and pets. Great story. Great company and an opportunity to do well.
BUY
BUY
January 8, 2020
The pet medicine industry continues to grow. There are few competitors. He's recommended ZTS many times before. People spend $3K on their pets. ZTS has pricing power.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
January 8, 2020
The pet medicine industry continues to grow. There are few competitors. He's recommended ZTS many times before. People spend $3K on their pets. ZTS has pricing power.
TOP PICK
TOP PICK
December 19, 2019
They make drugs for pets. $6.2 billion was spent in 2001 on pets and now it's over $15 billion. Each owner spend $3,000 on their pet, mostly out of pocket. The process to get a pet drug to market is faster than a drug for humans. Lots of growth. (Analysts’ price target is $135.31)
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
December 19, 2019
They make drugs for pets. $6.2 billion was spent in 2001 on pets and now it's over $15 billion. Each owner spend $3,000 on their pet, mostly out of pocket. The process to get a pet drug to market is faster than a drug for humans. Lots of growth. (Analysts’ price target is $135.31)
BUY
BUY
December 2, 2019
The companion animal market has grown very strongly in the developed world. This company has less exposure to livestock. They provide testing services to vets. He likes the company. He likes the long term prospects of the company but banks will do better if interest rates keep going up.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
December 2, 2019
The companion animal market has grown very strongly in the developed world. This company has less exposure to livestock. They provide testing services to vets. He likes the company. He likes the long term prospects of the company but banks will do better if interest rates keep going up.
COMMENT
COMMENT
November 8, 2019
They make pharmaceuticals for pets. The action today looks like it’s breaking down. The volume looks good but there’s been a lot of selling. He would be very cautious.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
November 8, 2019
They make pharmaceuticals for pets. The action today looks like it’s breaking down. The volume looks good but there’s been a lot of selling. He would be very cautious.
PAST TOP PICK
PAST TOP PICK
October 24, 2019
(A Top Pick Nov 07/18, Up 30%) Revenue split between pet care and livestock. Owners are increasingly willing to spend money on pets. Fragmented industry. Huge margins. 20 consecutive quarters of positive earnings surprises. Good name long-term. Bit pricey, but they can catch up.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
October 24, 2019
(A Top Pick Nov 07/18, Up 30%) Revenue split between pet care and livestock. Owners are increasingly willing to spend money on pets. Fragmented industry. Huge margins. 20 consecutive quarters of positive earnings surprises. Good name long-term. Bit pricey, but they can catch up.
TOP PICK
TOP PICK
October 18, 2019
The biggest livestock and pet medicine maker in the world. They have 300 R&D projects in the works. A solid long term uptrend in place. A recent technical buy signal has him thinking now is the time to buy. Yield 0.51% (Analysts’ price target is $132.00)
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
October 18, 2019
The biggest livestock and pet medicine maker in the world. They have 300 R&D projects in the works. A solid long term uptrend in place. A recent technical buy signal has him thinking now is the time to buy. Yield 0.51% (Analysts’ price target is $132.00)
TOP PICK
TOP PICK
September 26, 2019
People spend over $15 billion for over-the-counter drugs for their pets. There are no generic ones that compete and it's easier to bring to market (less testing) compared to meds for humans. (Analysts’ price target is $128.86)
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
September 26, 2019
People spend over $15 billion for over-the-counter drugs for their pets. There are no generic ones that compete and it's easier to bring to market (less testing) compared to meds for humans. (Analysts’ price target is $128.86)
PAST TOP PICK
PAST TOP PICK
September 11, 2019
(A Top Pick Sep 12/18, Up 37%) Healthcare for animals. 33x earnings. Industry is a high-margin business. Consumer doesn't have much pricing power. Greater global need for healthier livestock. Reported 20 consecutive quarters of positive earnings.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
September 11, 2019
(A Top Pick Sep 12/18, Up 37%) Healthcare for animals. 33x earnings. Industry is a high-margin business. Consumer doesn't have much pricing power. Greater global need for healthier livestock. Reported 20 consecutive quarters of positive earnings.
Showing 1 to 15 of 29 entries

Zoetis Inc(ZTS-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 8

Stockchase rating for Zoetis Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Zoetis Inc(ZTS-N) Frequently Asked Questions

What is Zoetis Inc stock symbol?

Zoetis Inc is a American stock, trading under the symbol ZTS-N on the New York Stock Exchange (ZTS). It is usually referred to as NYSE:ZTS or ZTS-N

Is Zoetis Inc a buy or a sell?

In the last year, 8 stock analysts published opinions about ZTS-N. 6 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Zoetis Inc.

Is Zoetis Inc a good investment or a top pick?

Zoetis Inc was recommended as a Top Pick by Paul Harris, CFA on 2020-10-26. Read the latest stock experts ratings for Zoetis Inc.

Why is Zoetis Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Zoetis Inc worth watching?

8 stock analysts on Stockchase covered Zoetis Inc In the last year. It is a trending stock that is worth watching.

What is Zoetis Inc stock price?

On 2020-11-25, Zoetis Inc (ZTS-N) stock closed at a price of $160.19.